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Abstract Bariatric revision surgery is associated with
several complications that can be attributed to decreased
quality of tissue and complexity of the surgery. A
laparoscopic sleeve gastrectomy is a simple technique with
potential advantages. Therefore, the results of this proce-
dure were evaluated as a revisional option. Fifty-one
patients underwent laparoscopic sleeve gastrectomy
(LSG). Indications for the LSG were insufficient weight
loss (34 patients, group 1) or vomiting (17 patients, group
2) following a laparoscopic adjustable gastric banding
(LAGB) or vertical banded gastroplasty (VBG). Patient
and procedure characteristics as well as outcome were
collected prospectively. From October 2006 to June 2010,
51 patients with a failed prior bariatic procedure (VBG or
LAGB) were converted to (L)SG. The conversion rate was
zero. The median procedure time was 99 min (range 54–
221) and hospital stay was 3 days (range 2–38). There was
no mortality after 30 days. Complications included bleeding
(six) and leakage of the staple line (seven). Mean follow-up
was 13.8 (2–46) months. LSG as revision surgery for
insufficient weight loss resulted in extra weight loss of
52.7%, and the overall extra weight loss was 49.3%. When
LSG was performed because of vomiting, 82% was able to
eat solid food at follow-up. Of the 65 pre-existent co-
morbidities, 21 were resolved and 18 improved. LSG as a
revision procedure is feasible. An additional weight loss
and further resolution of co-morbidity seem achievable,
however, at the cost of a high number of complications.
Therefore, revision bariatric surgery should be limited to




In the late 1990s, gastric banding (LAGB) and vertical
banded gastroplasty (VBG) were popular bariatric proce-
dures. Initially good results with 54–58% weight loss [1]
were reported. However, extended follow-up showed high
failure rates (20–56%) [2, 3]. The most common failures
are related to pouch dilation or slippage. Other causes could
be band erosion, tubing leakage, or port site trouble
(inversion, hernia, or pain) [4].
There are several options after a failure of a restrictive
procedure such as re-do banding in case of band-related
failure, conversion to Roux-en-Y gastric bypass (RYGBP),
duodenal switch (DS), or biliopancreatic diversion (BPD)
[5]. However, bariatric revision surgery is associated with a
higher complication rate than primary procedures [6]
independent of the used technique.
In 1998, the first laparoscopic sleeve gastrectomy (LSG)
was performed as a component of Hess’ biliopancreatic
diversion with duodenal switch (BPD-DS) [7]. The effect of
sleeve gastrectomy is believed to be based on restriction
and reduction of ghrelin by removal of the orexigenic cells
and accelerated gastric emptying [8, 9]. It was first used as
a two-step procedure for the superobese but showed good
weight loss and resolution of co-morbidities with low
complication rates [10–12]. Therefore, LSG becomes more
popular as a stand-alone procedure and long-term results
are promising [13].





OBES SURG (2012) 22:330–334
DOI 10.1007/s11695-011-0501-3The experience in our center with sleeve gastrectomy as
a primary procedure is now over 500 procedures. Because
of the advantages of LSG, this procedure was chosen as a
revision option after prior LAGB or VBG. These results
were evaluated in the present study.
Methods
Patients
From October 2006 to June 2010, 51 patients (11 men and
40 women) with a failed prior bariatic procedure (VBG or
LAGB) were converted to LSG. Group 1 had insufficient
weight loss (34 patients) and group 2 had complaints of
passage or vomiting (17 patients).
In group 1, the weight loss after revision surgery was
expressed as percentage of excess body mass index
(EBMI):
%EBMI loss ¼
preop BMI   current BMI   100
preop BMI   25
Operative Technique
All patients received low molecular weight heparin preoper-
ative for venous thromboembolismprophylaxis. Additionally,
pneumatic stockings (Sequential Compression Stockings®
(Covidien, Elancourt Fr)) were used during the intervention.
A second-generation cephalosporin (cephazoline 2.0 g
iv) was applied perioperative. The patient was posi-
tioned in French position (supine with legs apart and
arms abducted) with the surgeon standing between the
legs. The abdomen was insufflated with a Veress needle
at Palmer’s point to a pressure of 18 mmHg. A four or
five trocar technique was used. The first 12-mm visiport
trocar was placed 20 cm distal to the xiphoid process
for the 30° optical system. One 5-mm trocar was placed
just below the xiphoid process on the left side and the
other two trocars were placed in the mid-clavicular line
right and left side 5 cm distal to the costal margin (right
15-mm and left 12-mm trocar). The liver was retracted
with a 5-mm liver retractor. If the procedure was post-
LAGB, the band was freed of adhesions and the total
circumference was exposed by sectioning the gastro-
gastric tunnel covering the band. Then the band is
removed. On the judgement of the surgeon, a one-stage
or two-stage strategy is followed (proceed directly to
LSG or planned LSG after 3 months). Regardless of the
stage, no buttressing was used.
When LSG is done, the greater curvature of the stomach
was freed from the greater omentum, starting opposite the
crow’s foot, with the LigaSure® (Covidien, Elancourt Fr),
dissecting proximally until the left crus and angle of His were
reached and distally towards the pylorus sparing 6 cm of the
proximal antrum. The stomach was transected with an
Endogia®, loaded with one or two green and four blue
cartridges (average) (Covidien, Elancourt Fr), under guidance
of a 34-F orogastric tube pressed along the lesser curvature. If
the procedure was post-VBG, the transaction was up to the
former staplers. Band was removed if possible, split if
impossible (Marlex®). Due to dilatation of the pouch, a new
staplelinewasagainwithinthe oldstaplelineinallcases.The
excluded partof the stomach was extracted from the abdomen
through the somewhat enlarged 15-mm trocar site. This
15-mm fascia lesionisclosed with anEndoClose® (Covidien,
Elancourt Fr) with an absorbable suture. The gastric tube was
removed, CO2 released, and trocars removed. Skin was
closed intracutaneously.
Postoperative Management
Usually, patients were discharged at the third postoperative
day with liquid diet advised for 3 weeks. All patients
received Fragmin® (Pfizer, New York, USA) 5000eh once a
day and TED socks (Covidien, Elancourt Fr) for 4 weeks.
Meanwhile, 3 months of a PPI once a day was prescribed.
Data Collection
Prospectively collected data were patient and procedure
characteristics as well as outcome. In case of incompleteness
of data, a questionnaire was sent to the patients and the
patientswerecontactedbytelephone.Alldataarepresentedas
median (range) unless otherwise stated. No statistical evalu-
ation was performed due to the small study population.
Results
At the time of revision, median age was 39.2 years (range 19–
65 years) and median BMI was 41.0 kg/m
2 (25–61 kg/m
2).
The median BMI before the primary surgery was 45.3 kg/m
2
(range 35–77 kg/m
2) and post-primary surgery was 30.6 kg/
m
2 (range 23–61 kg/m
2).
The median procedure time was 99 min (range 54–221)
and hospital stay was 3 days (range 2–38). Mean follow-up
was 13.8 (2–46) months.
There was no mortality in this group. Of the 51
patients, 47 procedures were performed laparoscopically
of which 4 previously had open surgery, and 4
procedures were performed after prior open surgery.
There were no conversions and the open procedures
were prior open procedures and were planned open due
to expected adhesions (see flow chart).
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The main complications were one intraoperative
splenic lesion (2.0%), of which a hand-assisted splenectomy
was performed, five bleedings (9.8%) (one re-intervention)
and seven leakages of the staple line (14%) treated with two
re-interventions (3.9%), five (repeated) CT-guided drainages
(9.8%), and three endoscopically positioned stents (6%).
Extended length of stay associated with leakage was 13 days
(median 16 and range 4–38).
In the post-LAGB group (28 patients), in 15 cases (54%)
a “one-stage” strategy was followed and 13 times (46%) a
“two-stage” strategy. The complication rate in our “two-
stage” strategy was 7.7% (one bleeding), which was treated
conservatively. No leakage or abscesses occurred. In the
“one-stage” strategy, however, three bleedings (20%) and
five leakages (33%) occurred which led to five abscesses
which were treated by CT-guided drainages and IV anti-
biotics and in two cases by an endoscopically placed
covered stent (see Table 1).
Of the 51 patients, 65 obesity-related co-morbidities,
including hypertension in 16 (31%), type II diabetes
mellitus in 8 (16%), degenerative joint disease in 27
(49%), hyperlipidemia in 9 (18%), and sleep apnea in 5
(10%) existed.
LSG as a revision surgery for insufficient weight loss
resulted in extra weight loss of 52.7%, and the overall extra
weight loss was 49.3% (see Table 2). When LSG was
performed because of vomiting, 82% of the patients were
able to eat solid food at follow-up. Of the 65 pre-existent co-
morbidities, 21 were resolved and 18 improved (see Table 3).
Discussion
In the 1990s, gastric banding (LAGB) or VBG became
popular restrictive bariatric procedures. Initially good
results were achieved with a 54–58% weight loss [3].
However, longer follow-up showed high rates of failure
(20–56%) [1, 2] demanding revisional surgery. Conversion
to RYGBP, DS, or BPD [5] and sleeve gastrectomy (SG) are
available techniques following AGB or VBG. Most of these
revisions can be done laparoscopically.
LSG itself is a viable option in staged surgery in the
(high-risk) superobese and becomes more popular as a
definitive single-stage option for morbid obesity [6, 10].
LSG does not alter bowel continuity, and there are no
mineral and vitamin deficiencies, except potential vitamin
Table 1 Complication rates
Former procedure One stage (n) Two stage (n)
AGB 15 13
Leakage 5 (33%) 0 (0%)
Bleeding 3 (20%) 1 (7.7%)
VBG 23
Leakage 2 (8.6%) –
Bleeding 2 (8.6%) –
Complication rate 32% 7.7%
Table 2 Weight loss and BMI
Total group Group 1
(insufficient weight loss)
Pre-weight (mean, kg) 120.3 127.6
Post-weight (mean, kg) 99.8 103.7
Weight loss (kg) 20.5 23.9
Pre-BMI (mean) 39.8 43.2
Post-BMI (mean) 32,5 33.6
BMI loss (kg/m
2) −7.3 −9.6
% BMI loss 49.3 52.7
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primary LSG is very acceptable (5–10%) [15, 16], and the
mortality rate associated with this procedure is very low.
In our surgical center, we performed both LRYGBP and
LSG as bariatric procedures. In these particular cases where
revision is needed, also LRYGBP and LSG are both surgical
options. The indications for LSG as a revision option were
experience with this procedure, patients personal preference,
and relative contra-indications for other techniques such as
lots of drug use. The overall complication rate for (L)
SG as revision of AGB or VBG is higher compared to
LSG as a primary procedure (13–34%) [17–19]. The
different complication rates in primary versus revision
procedures are probably explained by trauma of the
inferior tissue, stapling in inflammatory tissue due to the
band, and dissection of former adhesions with possible
damage of compromised tissue. Also, a compromised
vascular supply of the superior aspect of the staple line,
due to dissection of the left crus, may be a factor.
The published expected %EBMI loss after revision LSG is
42–46% at 12 months of follow-up [17, 20]. These results are
slightly worse than after RYGPB where up to 60% is achievable
[21]. Also co-morbidities will further reduce or even resolve
after revision LSG in the majority of the treated patients. This
could be as much as 50% improvement [17, 21].
As mentioned in our series, we had a total complication
rate of 25% (13/51) with no mortality, which is acceptable
compared with literature (13–34%). The leakage rate of our
series was 14% (seven), i.e., two (8.7%) following VBG
and five following an AGB (17.9%). However, if our “two-
stage” strategy (46% of our cases) was performed after
AGB, no leakage or abscesses were reported. The only
complication in this group was bleeding which was treated
conservatively.
In our opinion, a waiting period of 3 months allows tissue
to regenerate in order to reduce the risk of leakage. At this
moment, there is still no evidence in literature about this.
In group 1 (insufficient weight loss), the %EBMI loss
was 52.7%, and the overall %EBMI loss was 49.3%, which
is comparable to earlier published results for LSG as a
revisional option [17]. There is still a discussion on the
exact definition of percent excess BMI. Defining a BMI of
25 kg/m
2, the upper limit of normal in line with current
anthropometric definitions of obesity as a target for weight
loss remains arbitrary. Using a lower than maximum ideal
body weight would decrease the percentage of weight loss.
As most other studies use a BMI of 25 as a starting point,
the same definition was used in the present study.
In our series, the co-morbidities improved in 28% and
even resolved in 32% of the patients. This is as good as
earlier published or even slightly better. We had one (2%)
uncontrollable bleeding of the spleen that was resolved
using a hand-assisted splenectomy. This was after an open
AGB with loss of adhesions. Our series is a relatively small
retrospective study with an intermediate follow-up of
14 months. But it is still one of the largest published series
using SG as a revision option for AGB and VBG.
In summary, we concluded that LSG is a feasible option
as a revision procedure after VBG or AGB with a high, but
acceptable, complication rate. In our opinion a “two-stage”
procedure should be followed to reduce leakage risks after
an initial AGB, and revision bariatric surgery should be
limited to expert (high volume) tertiary centers.
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